Repositorio Dspace

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study

Mostrar el registro sencillo del ítem

dc.contributor.author Romero-Riquelme, Mónica-Alejandra
dc.contributor.author Aspas-Requena, Gaspar
dc.contributor.author Lloret-Madrid, Pilar
dc.contributor.author Gil, Cristina
dc.contributor.author Aguiar, Eliana
dc.contributor.author Tormo, Mar
dc.contributor.author del-Bernal-del-Castillo, Teresa
dc.contributor.author Rodríguez-Arboli, Eduardo
dc.contributor.author Serrano, Josefina
dc.contributor.author Sánchez-García, Joaquin
dc.contributor.author Rodríguez-Medina, Carlos
dc.contributor.author Mariz, José-Mario
dc.contributor.author Ayala, Rosa
dc.contributor.author Martínez-López, Joaquin
dc.contributor.author Amigo, María-Luz
dc.contributor.author Vives, Susana
dc.contributor.author Algarra-Algarra, Lorenzo
dc.contributor.author García-Boyero, Raimundo
dc.contributor.author Brioso, Joana
dc.contributor.author Castano, Tamara
dc.contributor.author Bergua-Burgues, Juan-Miguel
dc.contributor.author Salamero, Olga
dc.contributor.author Bass-Maturana, María-Francisca
dc.contributor.author Colorado, Mercedes
dc.contributor.author García-Fortes, María
dc.contributor.author Sayas-Lloris, María-José
dc.contributor.author Vicente, Belén-Vidriales
dc.contributor.author Chillon, Carmen
dc.contributor.author Pérez-Santaolalla, Esther
dc.contributor.author Madrigal, María-Dolores
dc.contributor.author Labrador-Gómez, Jorge
dc.contributor.author García-Pérez, María-José
dc.contributor.author Casado-Calderon, Soledad
dc.contributor.author Pérez-Encinas, Manuel
dc.contributor.author Balerdi-Malcorra, Amaia
dc.contributor.author Rodríguez, María-Sole
dc.contributor.author Gómez-García, Lara-María
dc.contributor.author Herrera-Puente, Pilar
dc.contributor.author Arce-Fernández, Olga
dc.contributor.author Barrios-García, Manuel
dc.contributor.author Noriega, Victor
dc.contributor.author Fernández, Rosa
dc.contributor.author Mateos, Mamen
dc.contributor.author Lacalzada, Carolina
dc.contributor.author Almela-Gallego, Agata
dc.contributor.author García-Garay, María-Carmen
dc.contributor.author Couto, Carmen
dc.contributor.author Pérez-Simon, José-Antonio
dc.contributor.author Barragan-González, Eva
dc.contributor.author Montesinos, Pau
dc.date.accessioned 2026-10-28T08:18:44Z
dc.date.available 2026-10-28T08:18:44Z
dc.date.issued 2026-11
dc.identifier.citation Romero Riquelme MA, Aspas Requena G, Lloret-Madrid P, Gil C, Aguiar E, Tormo M, et al. Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3 -Mutated AML: The PETHRATIFY Study. American J Hematol. noviembre de 2026;101(11):2812-26. doi:10.1002/ajh.70488
dc.identifier.issn 0361-8609
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/29107
dc.description.abstract Mutations in FLT3 are present in approximately 30% of patients with AML. The addition of midostaurin (MIDO) to intensive chemotherapy (IC) became standard of care following the RATIFY trial, but comprehensive real-world data spanning the full adult age spectrum and including both FLT3-ITD and FLT3-TKD mutations remain limited. We retrospectively analyzed 1658 adults aged 14-85 years with newly diagnosed FLT3-mutated AML from 129 PETHEMA registry centers: 469 received IC + MIDO and 1189 IC alone. Composite complete remission was higher with IC + MIDO than IC (81.4% vs. 71.7%; p < 0.001) and Day 30 mortality was substantially lower (2.1% vs. 7.1%; p < 0.001). Median overall survival was 47.2 versus 19.3 months (HR 0.64; 95% CI, 0.53-0.76; p < 0.001), and the benefit was sustained after multivariable adjustment (HR 0.73; p = 0.017). In 261 propensity score-matched pairs, the effect was attenuated, remaining significant for event-free survival (HR 0.77; p = 0.029) and showing a nonsignificant trend for OS (HR 0.77; p = 0.06). Allogeneic hematopoietic stem cell transplantation in first remission was more frequent in the IC + MIDO cohort (48.9% vs. 41.3%; p = 0.023). Time-dependent analyses showed the largest MIDO effect among autologous and non-transplanted patients (OS HR 0.45; p = 0.138, and HR 0.69; p = 0.014, respectively). The benefit of MIDO was consistent irrespective of FLT3 mutation type, FLT3-ITD allelic burden, cytogenetic risk, and gender, while less improvement occurred among NPM1 wild type and secondary AML patients. This large real-world cohort confirms the survival benefit of MIDO plus IC across the full adult age spectrum, supporting its standard-of-care status in FLT3-mutated AML.
dc.language.iso eng
dc.publisher WILEY
dc.rights Atribución/Reconocimiento-NoComercial 4.0 Internacional 
dc.rights.uri https://creativecommons.org/licenses/by-nc/4.0/deed.es  *
dc.subject.mesh Adolescent
dc.subject.mesh Adult
dc.subject.mesh Aged
dc.subject.mesh Aged, 80 and over
dc.subject.mesh Female
dc.subject.mesh Humans
dc.subject.mesh Male
dc.subject.mesh Middle Aged
dc.subject.mesh Young Adult
dc.subject.mesh Antineoplastic Combined Chemotherapy Protocols/therapeutic use
dc.subject.mesh fms-Like Tyrosine Kinase 3/genetics
dc.subject.mesh Leukemia, Myeloid, Acute/genetics/drug therapy/mortality/therapy
dc.subject.mesh Mutation
dc.subject.mesh Nucleophosmin
dc.subject.mesh Registries
dc.subject.mesh Remission Induction
dc.subject.mesh Retrospective Studies
dc.subject.mesh Staurosporine/analogs & derivatives/therapeutic use/administration & dosage/analogs & derivatives
dc.subject.mesh Treatment Outcome
dc.title Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 42671173
dc.relation.publisherversion https://onlinelibrary.wiley.com/doi/10.1002/ajh.70488
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1002/ajh.70488
dc.journal.title American Journal of Hematology
dc.identifier.essn 1096-8652


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial 4.0 Internacional  Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial 4.0 Internacional 

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta